Xibrom Related Published Studies
Well-designed clinical trials related to Xibrom (Bromfenac Ophthalmic)
Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. [2011.09]
PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Study. [2011.08.20]
Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular
inflammation and pain. [2011]
Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. [2010.12]
Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. [2009.10]
Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. [2009.06]
Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. [2009.05]
Topical bromfenac 0.09% vs. ketorolac 0.4% for the control of pain, photophobia, and discomfort following PRK. [2009.02]
Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor. [2008.12]
Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. [2008.09]
In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. [2007.09]
Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. [2007.09]
Effects of an opioid (oxycodone/paracetamol) and an NSAID (bromfenac) on driving ability, memory functioning, psychomotor performance, pupil size, and mood. [2006.06]
Well-designed clinical trials possibly related to Xibrom (Bromfenac Ophthalmic)
NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. [2010.02]
Other research related to Xibrom (Bromfenac Ophthalmic)
[Efficacy observation of 0.1% bromfenac sodium eye drops on relieving the
post-LASEK irritative symptoms]. [Article in Chinese] [2015]
[Comparison of clinical effects of bromfenac sodium ophthalmic solution 0.1%
versus glucocorticoids for post-LASEK usage]. [Article in Chinese] [2015]
Bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for control of
ocular inflammation and prevention of cystoid macular edema after
phacoemulsification. [2013]
Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for
exudative age-related macular degeneration. [2012]
A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. [2011.12]
Prostaglandin E(2) Inhibition of Ketorolac 0.45%, Bromfenac 0.09%, and Nepafenac 0.1% in Patients Undergoing Phacoemulsification. [2011.11.18]
Safety and efficacy of bromfenac ophthalmic solution () dosed once daily for postoperative ocular inflammation and pain. [2011.11]
Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom. [2011.02]
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK. [2011]
Efficacy and safety of bromfenac for the treatment of corneal ulcer pain. [2010.10]
Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. [2009.11]
Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. [2009.10]
Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. [2009.09.02]
Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. [2009.06]
Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. [2009.01.30]
24-hour evaluation of the ocular distribution of (14)c-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. [2008.08]
The systemic safety of bromfenac ophthalmic solution 0.09%. [2007.12]
Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. [2007.09]
Bromfenac Ophthalmic Solution 0.09% (Xibrom) for Postoperative Ocular Pain and Inflammation. [2007.04.18]
Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis. [2007]
Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. [2006.06]
A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. [2006.04]
Other possibly related research studies
Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. [2006.08]
Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. [2006.02]
Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. [2006.02]
Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. [2007.02]
Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). [2007.11]
Topical ocular delivery of NSAIDs. [2008.06]
Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model. [2009.03]
Cytotoxicity of topical medications used for infection and inflammation control after cataract surgery in cultured corneal endothelial cells. [2010.09]
NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid
macular edema. [2010]
Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of
inflammation after cataract surgery. [2013]
|